EcoDrugPlus

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSVPAG00000011840
Gene Symbol: NR1H3
1 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSVPAG00000006065
Gene Symbol: NR1H4
1 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSVPAG00000006590
Gene Symbol: NR3C1
1 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSVPAG00000006935
Gene Symbol: NR3C2
1 Cross references
212 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSVPAG00000001193
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSVPAG00000005514
Gene Symbol: PNLIP
1 Cross references
300 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSVPAG00000005876
Gene Symbol: PPARD
1 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSVPAG00000011059
Gene Symbol: PPARG
1 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSVPAG00000006612
Gene Symbol: PIK3CA
1 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSVPAG00000010070
Gene Symbol: PIK3CB
1 Cross references
215 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSVPAG00000008625
Gene Symbol: PIK3CG
1 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSVPAG00000000012
Gene Symbol: PDE10A
1 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).